1,1'-Carbonyldiimidazole → 4-[3-(5-Formyl-thiazol-2-yl)-1-(4-methyl-cyclohexyl)-ureido]-piperidine-1-carboxylic acid tert-butyl ester

HRID 253864

Reaktionsgleichung

[CH:1]([C:3]1[S:7][C:6]([NH2:8])=[N:5][CH:4]=1)=[O:2].[C:9]([O:13][C:14]([N:16]1[CH2:21][CH2:20][CH:19]([NH:22][CH:23]2[CH2:28][CH2:27][CH:26]([CH3:29])[CH2:25][CH2:24]2)[CH2:18][CH2:17]1)=[O:15])([CH3:12])([CH3:11])[CH3:10].C1N=CN([C:35](N2C=NC=C2)=[O:36])C=1>CN(C1C=CN=CC=1)C.C1COCC1>[C:9]([O:13][C:14]([N:16]1[CH2:21][CH2:20][CH:19]([N:22]([CH:23]2[CH2:28][CH2:27][CH:26]([CH3:29])[CH2:25][CH2:24]2)[C:35]([NH:8][C:6]2[S:7][C:3]([CH:1]=[O:2])=[CH:4][N:5]=2)=[O:36])[CH2:18][CH2:17]1)=[O:15])([CH3:12])([CH3:10])[CH3:11]

Komponenten

Reaktionsbedingungen

Temperatur: 65 °C

Versuchsvorschrift

Prepared in a manner similar to general procedure (C) using 5-formyl-2-aminothiazole (1.88 g, 14.6 mmol), 4-(4-methyl-cyclohexylamino)-piperidine-1-carboxylic acid tert-butyl ester (4.32 mg, 14.6 mmol), catalytic DMAP, CDI (2.60 g, 1.1 mmol) and THF with heating to 65° C. afforded 1.77 g (27%) of the desired product after purification.

Aufarbeitung

customPrepared in a manner similar to general procedure (C)

Quellen und Nachweise

ORD-Eintrag: ord-22c53b1fc3d849d1a6e3060e342c94e5
Quelldatensatz: uspto-grants-2011_01
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US07872139B2

Verknüpfte Notizen

Wird geladen…